Advanced kidney cancer "immune and targeted" first-line treatment! The Opdivo-Cabometyx program was approved by the FDA and beats Sutt!
Last Update: 2021-03-04
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Treatment of Renal Cell Carcinoma (RCC), Opdivo's approved adaptation is: (1) for previous use in Patients with advanced RCC who have been treated with anti-angiogenesis therapy; (2) patients with advanced RCC who are in the first line of treatment with Yervoy (ipilimumab, iplimma, anti-CTLA-4 monoantigen) are treated with medium- or high-risk advanced RCC.
() Origin: U.S. Food and Drug Administration approves OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) as First-line Treatment for Patients with Advanced Renal Cell Carcinoma
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.